FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
|Slideshows|July 29, 2015
6 Fascinating Tidbits: July Primary Care Roundup
Author(s)Susan Kweskin
Advertisement
We found 6 stories we think you'll want to know about. . . eg, the 4th dimension is now a clinical reality; a novel drug delivery system has just been deployed (drones); and there's an innovative -- and much quicker -- way for your patients to get their caffeine buzz.  Â
Advertisement
Related to this article
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
Advertisement
Advertisement
Trending on Patient Care Online
1
HIV Testing Before and During PrEP: Getting It Right
2
9 Drugs Approved for Primary Care: Q3 2026
3
Immunizing Against Pain and Fear: Rethinking the Vaccination Experience
4
Starting the HIV PrEP Conversation in Primary Care and Pharmacy
5